Long-term safety of recombinant growth hormone

被引：1
|
作者：
Carel, J.-C.
Coste, J.
机构：
[1] Hop Robert Debre, APHP, Serv Endocrinol Diabetol Pediat, F-75935 Paris 19, France
[2] Hop Robert Debre, APHP, Inserm U690, F-75935 Paris, France
来源：
ARCHIVES DE PEDIATRIE | 2007年 / 14卷 / 06期
关键词：
growth hormone; cancer; tolerance; adverse effects;
D O I：
10.1016/j.arcped.2007.04.004
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：615 / 617
页数：3
相关论文
共 50 条
  • [21] Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk
    Boguszewski, Cesar Luiz
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (06)
  • [22] Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy
    Giavoli, C
    Porretti, S
    Ronchi, CL
    Cappiello, V
    Ferrante, E
    Orsi, E
    Arosio, M
    Beck-Peccoz, P
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (06): : 740 - 743
  • [23] Long-Term Surveillance of Growth Hormone Therapy
    Rosenfeld, Ron G.
    Cohen, Pinchas
    Robison, Leslie L.
    Bercu, Barry B.
    Clayton, Peter
    Hoffman, Andrew R.
    Radovick, Sally
    Saenger, Paul
    Savage, Martin O.
    Wit, Jan M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (01): : 68 - 72
  • [24] Long-term safety of growth hormone in adults and adolescents with growth hormone deficiency: An overview of the full-cohort in KIMS
    Johannsson, Gudmundur
    Touraine, Philippe
    Feldt-Rasmussen, Ulla
    Pico, Antonio
    Vila, Greisa
    Carlsson, Martin
    van Beek, Andre P.
    Wajnrajch, Michael P.
    Gomez, Roy
    Yuen, Kevin C. Y.
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 140 - 140
  • [25] Long-term response to recombinant human growth hormone treatment: a new predictive mathematical method
    G. Migliaretti
    S. Ditaranto
    C. Guiot
    S. Vannelli
    P. Matarazzo
    N. Cappello
    I. Stura
    F. Cavallo
    [J]. Journal of Endocrinological Investigation, 2018, 41 : 839 - 848
  • [26] Long-term response to recombinant human growth hormone treatment: a new predictive mathematical method
    Migliaretti, G.
    Ditaranto, S.
    Guiot, C.
    Vannelli, S.
    Matarazzo, P.
    Cappello, N.
    Stura, I.
    Cavallo, F.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2018, 41 (07): : 839 - 848
  • [27] Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature
    Kemp, SF
    Kuntze, J
    Attie, KM
    Maneatis, T
    Butler, S
    Frane, J
    Lippe, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09): : 5247 - 5253
  • [28] How concerned should we be over the long-term safety of growth hormone therapy?
    Tritos, Nicholas A.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (02): : 79 - 81
  • [29] Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns
    Goujard, Cecile
    Salenave, Sylvie
    Briot, Karine
    Chanson, Philippe
    Grimon, Gilles
    Kamenicky, Peter
    [J]. LANCET, 2020, 395 (10232): : 1304 - 1304
  • [30] Efficacy and safety of the treatment of growth hormone deficient children (GHD) with the recombinant hGH Omnitrope®: 84-month long-term data
    Romer, Tomasz
    Peter, Ferenc
    Koehler, Brygida
    Wasikowa, Renata
    Walczak, Mieczyslaw
    Korman, Eugeniusz
    Starzyk, Jerzy
    Berghout, Alexander
    Zabransky, Markus
    Saenger, Paul H.
    [J]. HORMONE RESEARCH, 2009, 72 : 492 - 492
12345